Transactions
Vertex completes $85-a-share cash buyout of Crinetics
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026. Holders get $85.00 a share in cash. Vertex puts the aggregate consideration at about $10.0 billion. The merger agreement was signed July 6. Crinetics asked Nasdaq to suspend CRNX trading before the open on the closing day.
